Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial ResultsGlobeNewsWire • 10/27/22
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell LymphomaGlobeNewsWire • 10/03/22
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCLGlobeNewsWire • 09/27/22
Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc ConferenceGlobeNewsWire • 09/23/22
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Oncternal Therapeutics, Inc.'s (ONCT) CEO Dr. James Breitmeyer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/02/22
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCLGlobeNewsWire • 07/14/22
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 CongressGlobeNewsWire • 06/10/22
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 CongressGlobeNewsWire • 06/10/22
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022GlobeNewsWire • 06/02/22
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022GlobeNewsWire • 05/26/22
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial ResultsGlobeNewsWire • 05/05/22
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial ResultsGlobeNewsWire • 04/28/22
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell LymphomaGlobeNewsWire • 04/13/22
Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/10/22
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/10/22